Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
By Nikita Chaurasia  Date: 2020-05-18

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial for assessing a possible coronavirus vaccine.

The Prime Minister of Canada, Justin Trudeau made this announcement on Saturday during his daily address to the nation.

Trudeau stated that research and development require time, and should be done right. However, despite the fact, this is a good news. The National Research Council would be working closely alongside the manufacturers, so in case the clinical trials are a success, the coronavirus vaccine can be manufactured and distributed at scale.

The clinical trials have been authorized by Health Canada and would be carried out at the CCfV (Canadian Centre for Vaccinology) at the Dalhousie University, Halifax. The CCfV team comprises 45 people working together on a potential vaccine candidate from CanSino Biologics.

Health Canada, while speaking about the trial, stated that the approval for going ahead with the trial was done after a careful review of the submitted trial application, which fulfilled the necessary quality and safety requirements.

Researchers stated that approximately 600 participants would be required to commence the clinical study.

Scott Halperin, CCfV Director and professor of immunology, pediatrics, and microbiology at Dalhousie University, stated that they would be further building upon the trials that have already started in China.   

Halperin further added that a vaccine strain known as Ad5-nCoV utilizes another virus which is modified to not cause infection within humans. It expresses a COVID-19 antigen called spike protein on its surface. If the trial participants create antibodies to tackle this antigen, then the formulation might prove helpful against the coronavirus.

Halperin hopes that the clinical trials would start in the coming two weeks once the team receives its approval from the ethics board.

Less than 100 participants of different ages would be tested in Phase 1. Phase 2 is expected to have more than 500 participants ranging between 18 to 85 years of age.

 

Source credit: https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

CACI International Inc. buys out Ascent Vision Technologies LLC
CACI International Inc. buys out Ascent Vision Technologies LLC
By Nikita Chaurasia

America-based IT giant CACI International Inc. has lately declared the acquisition of Ascent Vision Technologies LLC in a bid to expand its capabilities in multidomain intelligence and unmanned aircraft systems. For those uninitiated, Ascent Vision ...

New research exposes hidden vulnerability in novel Coronavirus
New research exposes hidden vulnerability in novel Coronavirus
By Nikita Chaurasia

The research led by Monica Olvera de la Cruz, Lawyer Taylor Professor of Materials Science and Engineering, and Baofu Qiao, a research assistant professor at the Northwestern University, have reportedly discovered a new vulnerability in the SARS-CoV-...

Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
By Nikita Chaurasia

Lately, China-based leading developer of software application for IoT (Internet of Things) Borqs Technologies Inc. has gained significant attention upon launching its mobile smart tracking solution called BeSmartTrack™. The launch event reporte...

Fractyl raises series E funding of USD 55 million for diabetes cure
Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes. As per the trusted sources, the capital will be invested on mass-b...

Nokia Corp. partners with IISc to improve telecommunication solutions
Nokia Corp. partners with IISc to improve telecommunication solutions
By Nikita Chaurasia

Finnish multinational telecommunications giant Nokia Corporation has recently made it to the headlines after entering into a joint venture agreement with IISc (Indian Institute of Science) to launch the Nokia CoE (Centre of excellence) for Networked ...